TO: |
The Securities Commissions in each of the Provinces of Canada |
1. |
this certificate is delivered pursuant to section 2.20 of National Instrument 54-101 Communication with Beneficial Owners of Securities of a Reporting Issuer (“NI 54-101) and in connection with the mailing of the Corporation’s proxy-related materials for its Annual and Special Meeting to be held on November 30, 2009 (the “Meeting”); |
2. |
the Corporation has arranged to have proxy-related materials for the Meeting sent in compliance with NI 54-101 to all beneficial owners at least 21 days before the date fixed for the Meeting; |
3. |
the Corporation has arranged to have carried out all of the requirements of NI 54-101 in addition to those prescribed in paragraph 2 above; and |
4. |
with respect to the Meeting, the Corporation is relying upon section 2.20 of NI 54-101 to abridge the time prescribed in subsection s. 2.2(1) and 2.5(1) of NI 54-101. |
LORUS THERAPEUTICS INC. | ||
By: |
“Elizabeth Williams” | |
Elizabeth Williams
Director of Finance and Acting Chief Financial Officer |